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Abstract: Background: Sympathetic dysfunction can be evaluated by heart rate reserve (HRR) with
exercise test. Objectives: To determine the value of HRR in predicting outcome of patients with
hypertrophic cardiomyopathy (HCM). Methods: We enrolled 917 HCM patients (age = 49 ± 15 years,
516 men) assessed with exercise stress echocardiography (ESE) in 11 centres. ESE modality was
semi-supine bicycle in 51 patients (6%), upright bicycle in 476 (52%), and treadmill in 390 (42%).
During ESE, we assessed left ventricular outflow tract obstruction (LVOTO), stress-induced new
regional wall motion abnormalities (RWMA), and HRR (peak/rest heart rate, HR). By selection,
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all patients completed the follow-up. Mortality was the predetermined outcome measure Results:
During ESE, RWMA occurred in 22 patients (2.4%) and LVOTO (≥50 mmHg) in 281 (30.4%). HRR
was 1.90 ± 0.40 (lowest quartile ≤ 1.61, highest quartile > 2.13). Higher resting heart rate (odds ratio
1.027, 95% CI: 1.018–1.036, p < 0.001), older age (odds ratio 1.021, 95% CI: 1.009–1.033, p < 0.001), lower
exercise tolerance (mets, odds ratio 0.761, 95% CI: 0.708–0.817, p < 0.001) and resting LVOTO (odds
ratio 1.504, 95% CI: 1.043–2.170, p = 0.029) predicted a reduced HRR. During a median follow-up
of 89 months (interquartile range: 36–145 months), 90 all-cause deaths occurred. At multivariable
analysis, lowest quartile HRR (Hazard ratio 2.354, 95% CI 1.116–4.968 p = 0.025) and RWMA (Hazard
ratio 3.279, 95% CI 1.441–7.461 p = 0.004) independently predicted death, in addition to age (Hazard
ratio 1.064, 95% CI 1.043–1.085 p < 0.001) and maximal wall thickness (Hazard ratio 1.081, 95% CI
1.037–1.128, p < 0.001). Conclusions: A blunted HRR during ESE predicts survival independently of
RWMA in HCM patients.
Keywords: autonomic dysfunction; hypertrophic cardiomyopathy; stress echocardiography
1. Introduction
The assessment of mortality risk patients with hypertrophic cardiomyopathy (HCM)
and little or no symptoms is a challenging task, and several approaches targeted on
different physiologic variables have been proposed [1–3]. In particular, exercise stress
echocardiography (ESE) provides a comprehensive information on dynamic left ventricular
outflow tract gradient (LVOTG) [4] and regional wall motion abnormalities (RWMA) due
to myocardial ischemia [5]. A normal heart rate reserve (HRR) is associated with integrity
of cardiac autonomic function [6]. Since the three parameters focus on three different,
important and largely unrelated pathophysiological targets, our study hypothesis is that
left ventricular outflow tract obstruction (LVOTO), RWMA, and HRR during ESE may
all independently contribute to improved risk stratification of HCM patients. To test this
hypothesis, we evaluated LVOTG, RWMA, and HRR during ESE for predicting survival
in HCM by interrogating the ESE multicentre data base built over the last 30 years with
different generations of SE [7–9], and currently ongoing with SE 2020 [10].
2. Materials and Methods
2.1. Patients Population
Data prospectively obtained from 1984 to 2019 from 917 consecutive HCM patients
were then retrospectively analysed. Of them, 608 were previously reported with shorter
follow-up [9], and 309 were enrolled in the SE 2020 study-subproject SEHCA (Stress
echo in hypertrophic cardiomyopathy) [10]. Diagnosis of HCM was based on existing
guidelines [1]. Phenocopies such as infiltrative/storage disease (e.g., Fabry, amyloid) were
carefully excluded.
All patients initially considered were in sinus rhythm and met the following inclusion
criteria at study entry: (1) a resting echocardiogram of at least satisfactory technical quality
(2) left ventricular ejection fraction >45%; (3) New York Heart association class I, II or III
(with capability to exercise); (4) no known coronary artery disease; (5) no other prognosis-
limiting disease.
Of this initial population of 970 patients, 53 were excluded from further data analysis
for one of the following reasons: 1- Follow-up data were not available (n = 40 patients); 2-
history of coronary artery disease at time of enrolment (n = 13). The remaining 917 HCM
patients were included in the present study population by 11 specialist referral centers for
HCM (Almada, Benevento, Belgrade, Edegem, Florence, La Coruña, Naples, Pisa, Porto
Alegre, Rome, and Szeged) from 7 countries (Belgium, Brazil, Hungary, Italy, Portugal,
Serbia, and Spain). All readers were accredited with specific credentialing process via
web [11].
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HCM was defined by a wall thickness ≥15 mm in one or more left ventricular myocar-
dial segments that is not explained solely by loading conditions capable of producing the
magnitude of left ventricular hypertrophy observed [2]. The study protocol was reviewed
and approved by the institutional ethics committees as a part of the SE 2020 study (148-
Comitato Etico Lazio-1, 16 July 2016; Clinical trials. Gov Identifier NCT 030.49995). The
study was funded partly by travel grants of the Italian Society of Echocardiography and
Cardiovascular Imaging with dedicated sessions during national meetings. No support
from industry was received.
2.2. Resting and Stress Echocardiography
Resting transthoracic echocardiography and ESE were performed by experienced
cardiologists according to recommendations [11–13]. A new RWMA was defined as an
increase of at least 1 grade in at least 2 segments at peak stress in a 17-segment model
of the left ventricle [12,13]. During exercise, LVOTO was defined as a gradient ≥50 mm
Hg [14,15] as recommended by current guidelines [14]. Exercise-induced hypotension was
defined as a fall of systolic blood pressure ≥20 mm Hg during exercise or an attenuated
response to exercise (<20 mm Hg from baseline) [2].
The risk score for sudden cardiac death was calculated according to guidelines [2] as
previously detailed [9].
2.3. Heart Rate Reserve
A 12 lead ECG was obtained during ESE and information on heart rate (rest and peak
values) archived [16]. The ratio of peak/baseline heart rate was taken as HRR [17]. A total
preparation (nurse + sonographer) time of about 15 min allowed the patient to reach a
baseline condition prior to stress.
2.4. Follow-Up Data
All-cause death was the only outcome measure [18].
2.5. Statistical Analysis
Categorical data are expressed as number of subjects and percentage while continu-
ous data are expressed as mean ± standard deviation or median (minimum–maximum)
depending on distribution of variables. We divided HCM patients in quartiles, based on
HRR results. For continuous variables intergroup differences were tested with one-way
analysis of variance and inter-group comparison by Bonferroni or Kruskal–Wallis followed
by Mann–Whitney test as appropriate. Chi-square test or Fisher exact test were used to
compare the distribution of categorical variables among groups.
Independent predictors of the lowest HRR quartile were assessed by multivariable
logistic regression analysis. Odds ratios (OR’s) with the corresponding 95% confidence
interval (CI) were estimated A significance of 0.05 was required for a variable to be included
into the multivariate model, while 0.1 was the cut-off value for exclusion.
Event-free survival related to the endpoints of interest was estimated using the Kaplan–
Meier method and survival curves were compared by means of the Log-Rank test. Uni-
variate Cox proportional hazards model was used to identify candidate predictors for
selected endpoints. All variables with p < 0.10 at univariate analysis were considered for
the inclusion in multivariate Cox proportional hazards model. The final multivariable
models were obtained excluding just those variables causing collinearity evaluated using
the variance inflation factor. None of the variables considered in the analysis violated the
non-proportionality of hazard assumption according to the Schoenfeld test. Hazard ratios
(HR’s) with the corresponding 95% CI were estimated. The incremental value of HRR was
evaluated comparing multivariable models with and without HRR using global X2 value
to evaluate improvement of goodness-of-fit as well as continuous net reclassification index
(NRI) to assess improvement in risk stratification. Statistical significance was set at p < 0.05.
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All analyses were performed using STATA (STATACorp. Stata statistical software: Release
14, STATACorp LP, College Station, TX, USA) and R version 3.6.
3. Results
3.1. Patient Characteristics
We enrolled 917 HCM patients (age = 49 ± 15 years, 516 men). The exercise modality
was semi-supine bicycle in 51 patients (6%), upright bicycle in 476 (52%), and (peak or
immediately post-exercise) treadmill in 390 (42%).
Four groups were identified: Highest quartile HRR > 2.13 (224 patients, 24.4%),
HRR 1.88–2.13 (227 patients, 24.8%), HRR 1.62–1.87 (237 patients, 25.8%) and lowest
quartile ≤1.61 (229 patients, 25.0%). Patients with lowest quartile had more advanced age
and higher functional class, were more often on therapy and showed at least moderate
mitral regurgitation on resting echocardiogram (Table 1).


















Age (years) 49 ± 15 43 ± 15 48 ± 15 * 50 ± 16 * 53 ± 14 *ˆ <0.001
Male gender, n (%) 516 (56.3%) 123 (54.9%) 126 (55.5%) 140 (59.1%) 127 (55.5%) 0.792
BSA (m2) 1.89 ± 0.21 1.86 ± 0.19 1.85 ± 0.21 1.91 ± 0.23 1.95 ± 0.20 *ˆ 0.001
NYHA
functional class 1.5 ± 0.6 1.3 ± 0.5 1.4 ± 0.6 * 1.6 ± 0.6 * 1.8 ± 0.7 *ˆ
§ <0.001
LV end-diastolic
diameter (mm) 52.7 ± 18.3 47.6 ± 9.4 52.3 ± 18.9 53.4 ± 17.9 57.5 ± 23.3* 0.002
LV end-systolic
diameter (mm) 27.0 ± 7.3 27.2 ± 6.6 26.7 ± 6.9 26.2 ± 7.1 27.8 ± 8.4 0.430
Maximal wall
thickness (mm) 20.9 ± 5.4 20.2 ± 5.4 21.2 ± 5.3 20.7 ± 5.4 21.4 ± 5.4 0.126
≥Moderate MR,
n (%) 95/672 (14.1%) 19/203 (9.4%) 25/179 (14.0%) 27/172 (15.7%) 24/118 * (20.3%) 0.048
Beta-blockers, n (%) 383 (41.8%) 81 (36.2%) 104 (45.8%) 98 (41.4%) 100 (43.7%) 0.189
Calcium-channel
blockers n (%) 91 (9.9%) 10 (4.5%) 16 (7%) 30 (12.7%) 35 (15.3%) <0.001
Diuretics, n (%) 110 (12.3%) 13 (5.8%) 23 (10.1%) 33 (13.9%) * 44 (19.2%) *ˆ <0.001
ESC risk score SCD 5.5 ± 7.4 5.8 ± 6.6 6.1 ± 8.5 4.4 ± 6.6 5.5 ± 7.6 0.269
* p < 0.05 vs. group 1, ˆ p < 0.05 vs. group 2, § p < 0.05 vs. group 3.
3.2. SE Positivity Criteria
Exercise was interrupted for symptoms (angina and/or dyspnea) in 239 patients (26.1%).
LVOTO was present in 150 patients (16.4%) at rest (including Valsalva) and in 281 pa-
tients (30.4%) at peak stress. RWMA were present in 12 patients (1.3%) at rest and in 34
(3.7%) at peak stress, with new or worsening RWMA in 22 patients (2.4%). An example of
normal wall motion, development of LVOTO and abnormal HRR during ESE in a patient
with HCM is shown in Figure 1.
HCM patients in the lowest quartile showed more frequent dynamic obstruction, and
poorer exercise tolerance (Table 2).
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Figure 1. The stress echo protocol. Rest (A,C) and peak stress (B,D). (A,B): Regional function is nor-
mal. EKG lead shows a blunted HRR response (rest = 54 bpm; peak exercise = 69 bpm; HRR = 1.27). 
(C,D): Continuous wave Doppler tracing of LVOTG (rest = 32 mmHg; peak exercise = 67 mmHg). 
During ESE, the patient shows, a significant LVOTG and an abnormally reduced HRR. 
HCM patients in the lowest quartile showed more frequent dynamic obstruction, and 
poorer exercise tolerance (Table 2). 




(n = 917) 
Group 1 
HRR: >2.13 
(n = 224) 
Group 2 
HRR: 1.88–2.13 
(n = 227) 
Group 3 
HRR: 1.62–1.87 
(n = 237) 
Group 4 
HRR: ≤1.61 
(n = 229) 
p 
HR at rest (b/m) 70.9 ± 13.6 63.1 ± 8.8 68.9 ± 11.1 * 73.6 ± 13.2 *^ 77.6 ± 15.7 *^§ <0.001 
HR at peak (b/m) 132.3 ± 27.3 152.8 ± 20.0 138.1 ± 22.7 * 129.1 ± 22.7 *^ 110.0 ± 24.7 *^§ <0.001 
HRR 1.90 ± 0.40 2.44 ± 0.26 2.00 ± 0.08 * 1.76 ± 0.07 *^ 1.42 ± 0.15 *^§ <0.001 
SBP at rest (mmHg) 124.9 ± 16.5 122.6 ± 15.1 123.2 ± 17.3 126.0 ± 15.9 127.9 ± 17.2 *^ 0.001 
SBP at peak (mmHg) 161.5 ± 28.8 166.3 ± 28.5 161.0 ± 30.1 162.5 ± 27.5 156.1 ± 28.2 * 0.002 
WMSI at rest 1.01 ± 0.07 1.01 ± 0.09 1.01 ± 0.06 1.01 ± 0.06 1.00 ± 0.01 0.293 
WMSI at peak 1.01 ± 0.09 1.02 ± 0.10 1.02 ± 0.10 1.01 ± 0.09 1.00 ± 0.01 0.146 
WMSI 0.01 ± 0.05 0.01 ± 0.05 0.01 ± 0.05 0.01 ± 0.07 0.00 ± 0.01 0.157 
RWMA, n (%) 22 (2.4%) 10 (4.5%) 5 (2.2%) 5 (2.1%) 2 (0.9%) 0.091 
Figure 1. The stress echo protocol. Rest (A,C) and peak stress (B,D). (A,B): Regional function is
normal. EKG lead shows a blunted HRR response (rest = 54 bpm; peak exercise = 69 bpm; HRR = 1.27).
(C,D): Continuous wave Doppler tracing of LVOTG (rest = 32 mmHg; peak exercise = 67 mmHg).
During ESE, the patient shows, a significant LVOTG and an abnormally reduced HRR.

















HR at rest (b/m) 70.9 ± 13.6 63.1 ± 8.8 68.9 ± 11.1 * 73.6 ± 13.2 *ˆ 77.6 ± 15.7 *ˆ§ <0.001
HR at peak (b/m) 132.3 ± 27.3 152.8 ± 20.0 138.1 ± 22.7 * 129.1 ± 22.7 *ˆ 110.0 ± 24.7 *ˆ§ <0.001
HRR 1.90 ± 0.40 2.44 ± 0.26 2.00 ± 0.08 * 1.76 ± 0.07 *ˆ 1.42 ± 0.15 *ˆ§ <0.001
SBP at rest (mmHg) 124.9 ± 16.5 122.6 ± 15.1 123.2 ± 17.3 126.0 ± 15.9 127.9 ± 17.2 *ˆ 0.001
SBP at peak (mmHg) 161.5 ± 28.8 166.3 ± 28.5 161.0 ± 30.1 162.5 ± 27.5 156.1 ± 28.2 * 0.002
WMSI at rest 1.01 ± 0.07 1.01 ± 0.09 1.01 ± 0.06 1.01 ± 0.06 1.00 ± .01 0.293
WMSI at peak 1.01 ± 0.09 1.02 ± 0.10 1.02 ± 0.10 1.01 ± 0.09 1.00 ± 0.01 0.146
WMSI 0.01 ± 0.05 0.01 ± 0.05 0.01 ± 0.05 0.01 ± 0.07 0.00 ± 0.01 0.157
RWMA, n (%) 22 (2.4%) 10 (4.5%) 5 (2.2%) 5 (2.1%) 2 (0.9%) 0.091
LV EDV at rest
(mL, n = 660) 90.3 ± 37.6 85.1 ± 29.8 86.6 ± 33.7 71.3 ± 41.4 101.3 ± 44.7 0.0 1
LV EDV at peak
(mL, n = 284) 60.1 ± 27.8 68.9±27.8 68.7 ± 26.4 68.0 ± 31.6 65.5 ± 25.8 0.914
LV ESV at rest,
(mL, n = 428) 26.9 ± 7.2 27.3 ± 11.8 28.0 ± 14.1 28.3 ± 16.4 29.4 ± 14.7 0.561
LV ESV at peak,
(mL, n = 311) 20.1 ± 11.8 20.8±12.6 20.0 ± 11.4 19.6 ± 11.3 19.4 ± 11.7 0.749


















LV EF at rest (%) 68.2 ± 9.1 68.2 ± 8.9 68.0 ± 9.6 68.2 ± 8.5 68.2 ± 9.3 0.804
LV EF at peak (%) 72.5 ± 11.0 72.3 ± 13.1 72.2 ± 9.8 72.4 ± 10.5 73.9 ± 8.4 0.804
LVOTO at rest, n (%) 150 (16.4%) 14 (6.3%) 29 (12.8%) 39 (16.5%) * 68 (29.7%) *ˆ§ <0.001
LVOTO at peak,
n (%) 281 (30.7%) 52 (23.7%) 60 (27.1%) 76 (32.3%) 93 (42.1%) *ˆ <0.001
Mets 7.5 ± 3.2 9.4 ± 3.1 7.8 ± 2.6 * 7.1±3.0*ˆ 5.3 ± 2.4 *ˆ§ <0.001
* p < 0.05 vs. group 1; ˆ p < 0.05 vs. group 2; § p < 0.05 vs. group 3.
Blunted HRR (lowest quartile) was associated to higher resting heart rate (odds ratio 1.027,
95% CI:1.018–1.036, p < 0.001), older age (odds ratio 1.021, 95% CI: 1.009–1.033, p < 0.001), lower
exercise tolerance (mets, odds ratio 0.761, 95% CI:0.708–0.817, p < 0.001) and resting LVOTO
(odds ratio 1.504, 95% CI: 1.043–2.170, p = 0.029) predicted a reduced HRR. (Table 3).
Table 3. Univariate and multivariate predictors of lowest quartile of abnormal heart rate reserve (HRR).
Univariate Analysis Multivariate Analysis
OR (95% CI) p Value OR (95% CI) p Value
Age 1.029 (1.019–1.040) <0.001 1.021 (1.009–1.033) 0.001
Gender (male) 0.957 (0.708–1.293) 0.775
B-blocker therapy 1.109 (0.820–1.501) 0.501
NYHA functional class ≥ 2 3.653 (2.118–6.301) <0.001
Calcium channel blocker therapy 2.450 (1.475–4.069) 0.001
Type of exercise 1.460 (0.739–2.885) 0.276
Mets 0.729 (0.671–0.770) <0.001 0.761 (0.708–0.817) <0.001
Heart Rate at rest 1.050 (1.038–1.062) <0.001 1.027 (1.018–1.036) <0.001
LV ejection fraction 1.000 (0.983–1.048) 0.969
Maximal wall thickness 1.022 (0.994–1.050) 0.123
LVOTO at rest 3.121 (2.166–4.498) <0.001 1.504 (1.043–2.170) 0.029
RWMA 3.398 (0.778–14.452) 0.101
3.3. Outcome
During a median follow-up of 89 months (interquartile range: 28–118 months), 90 all-
cause deaths occurred. The event rate in the four quartiles (from the highest to the lowest
HRR) was 5.7, 9.3, 12.4, and 15.5 per 1000 person months (p = 0.004) (Figure 2).
At multivariable analysis, lowest quartile HRR (Hazard ratio 2.354, 95% CI 1.116–4.968,
p = 0.025), and RWMA (Hazard ratio 3.279, 95% CI 1.441–7.461 p = 0.004) independently
predicted death, in addition to age (Hazard ratio 1.064, 95% CI 1.043–1.085, p < 0.001) and
maximal wall thickness (Hazard ratio 1.081, 95% CI 1.037–1.128, p < 0.001).
At incremental analysis, global X2 of clinical model for the prediction of death in-
creased from 64.5 to 68.1 (p < 0.41) with the addition of HRR to RWMA, maximal wall
thickness and age and risk reclassification also significantly improved with NRI: 0.24 (95%
CI: 0.030–0.442, p = 0.025).
Beta-blocker use was equally distributed in the 4 quartiles (Table 1) and was not a
predictor of reduced HRR (Table 3). ESE was performed under beta-blockers in 534 patients,
and without beta-blockers in 383 patients. Beta-blocker use did not predict outcome (Table 4).
At univariate analysis the lowest quartile of HRR predicted survival in the subset studied
off (n = 524, Hazard ratio = 2.865—95% CI 1.353–6.067, p = 0.006) or on (n = 383, Hazard
ratio = 4.777—95% CI 1.078–21.777, p = 0.04) beta-blockers at the time of ESE.




Figure 2. Survival curves based on HRR. Survival improves with higher values of (split in 4 quartiles). 
At multivariable analysis, lowest quartile HRR (Hazard ratio 2.354, 95% CI 1.116–
4.968, p = 0.025), and RWMA (Hazard ratio 3.279, 95% CI 1.441–7.461 p = 0.004) inde-
pendently predicted death, in addition to age (Hazard ratio 1.064, 95% CI 1.043–1.085, p < 
0.001) and maximal wall thickness (Hazard ratio 1.081, 95% CI 1.037–1.128, p < 0.001). 
At incremental analysis, global X2 of clinical model for the prediction of death in-
creased from 64.5 to 68.1 (p < 0.41) with the addition of HRR to RWMA, maximal wall 
thickness and age and risk reclassification also significantly improved with NRI: 0.24 (95% 
CI: 0.030–0.442, p = 0.025). 
Beta-blocker use was equally distributed in the 4 quartiles (Table 1) and was not a 
predictor of reduced HRR (Table 3). ESE was performed under beta-blockers in 534 pa-
tients, and without beta-blockers in 383 patients. Beta-blocker use did not predict outcome 
(Table 4). At univariate analysis the lowest quartile of HRR predicted survival in the sub-
set studied off (n = 524, Hazard ratio = 2.865—95% CI 1.353–6.067, p = 0.006) or on (n = 383, 
Hazard ratio= 4.777—95% CI 1.078–21.777, p = 0.04) beta-blockers at the time of ESE. 
Table 4. Univariate and multivariate predictors of all-cause death. 
 Univariate Analysis Multivariate Analysis 
 HR (95% CI) p Value HR (95% CI) p Value 
Age (years) 1.059 (1.041–1.077) <0.001 1.064 (1.043–1.085) <0.001 
Gender (male) 1.060 (0.698–1.609) 0.785   
NYHA functional class >2 2.130 (1.177–3.854) 0.012   
B-blockers therapy 1.264 (0.807–1.978) 0.306   
Exercise hypotension 1.457 (0.956–2.222) 0.080   
ESC risk score 0.970 (0.932–1.010) 0.140   
Maximal wall thickness 1.042 (1.008–1.078) 0.015 1.081 (1.037–1.128) <0.001 
LVOTO at rest 1.492 (0.897–2.480) 0.123   
LVOTO at peak 1.086 (0.701–1.682) 0.711   
RWMA 2.956 (1.366–6.398) 0.006 3.279 (1.441–7.461) 0.005 
Mets 0.901 (0.836–0.970) 0.006   
HRR >2.13 1    
HRR: 1.88–2.13 1.742 (0.860–3.532) 0.123   
HRR: 1.62–1.87 2.311 (1.187–4.502) 0.014   
HRR ≤1.61 3.100 (1.620–5.930) 0.001  2.354 (1.116
 
0.025 
Figure 2. Survival curves based on HRR. Survival improves with higher values of (split in 4 quartiles).
Table 4. Univariate and multivariate predictors of all-cause death.
Univariate Analysis Multivariate Analysis
HR (95% CI) p Value HR (95% CI) p Value
Age (years) 1.059 (1.041–1.077) <0.001 1.064 (1.043–1.085) <0.001
Gender (male) 1.060 (0.698–1.609) 0.785
NYHA functional class ≥2 2.130 (1.177–3.854) 0.012
B-blockers therapy 1.264 (0.807–1.978) 0.306
Exercise hypotension 1.457 (0.956–2.222) 0.080
ESC risk score 0.970 (0.932–1.010) 0.140
Maximal wall thickness 1.042 (1.008–1.078) 0.015 1.081 (1.037–1.128) <0.001
LVOTO at rest 1.492 (0.897–2.480) 0.123
LVOTO at peak 1.086 (0.701–1.682) 0.711
RWMA 2.956 (1.366–6.398) 0.006 3.279 (1.441–7.461) 0.005
Mets 0.901 (0.836–0.970) 0.006
HRR > 2.13 1
HRR: 1.88–2.13 1.742 (0.860–3.532) 0.123
HRR: 1.62–1.87 2.311 (1.187–4.502) 0.014
HRR ≤ 1.61 3.100 (1.620–5.930) 0.001 0.025
4. Discussion
In HCM patients, a reduction of HRR Is associated with worse survival. The prognostic
value of HRR is observed in patients off and on beta-blockers at the time of testing. The
underlying likely mechanism of impaired HRR is a blunted sympathetic reserve [19]
leading to cardiac autonomic unbalance and increased vulnerability to life-threatening
electrical instability [20]. The blunted HRR is the simplest, the least used and perhaps the
most important of exercise-related risk stratification factors in HCM. Not only high heart
rate at rest but also poor exercise tolerance and low HR at peak exercise are associated with
a reduced HRR, and both contribute to its capability to stratify outcome.
4.1. Comparison with Previous Studies
Exercise-induced RWMA can predict an adverse outcome in HCM patients, but they
are detectable 1 out of 20 patients. LVOT obstruction is especially helpful for predicting
heart failure [9]. Less data are available with HRR in HCM, but all of them are consistent
with a higher functional or structural impairment and higher risk associated with reduced
HRR [6,21–23]. A blunted HRR during exercise in HCM is associated with myocardial
fibrosis by cardiac magnetic resonance [22,23], lower peak oxygen consumption by spiroer-
J. Clin. Med. 2021, 10, 1347 8 of 11
gometry [6,23,24]. Efthmiadis et al. evaluated 68 patients and found that all of the 5 patients
with adverse event showed severe chronotropic incompetence [21]. Luo et al. found in
273 HCM patients that a preserved heart rate increase during stress was associated with
0% death rate compared to 2% in patients with blunted (<80%) HRR [22]. In another
large, retrospective, multicentre study of 681 consecutive HCM population with a median
follow-up of 4.2 years, Magri showed that HCM patients with chronotropic incompetence
have higher mortality [6].
Previous studies used slightly different methodology for assessing chronotropic reserve,
considering the percentage of age—predicted peak heart rate or adopting cutoff lower in
patients on (<62%) or off beta-blockers (<80%) [21,22]. Our results suggest that this simply
definable, easily accessible parameter is also able to identify HCM patients at risk for future
cardiac events. We have previously used the same methodology in pharmacologic stress
imaging studies, and proved that HRR shows independent value over inducible RWMA in
patients with chronic coronary syndromes, independently of the beta-blocker therapy [19]. In
HCM patients the risk associated with HRR is best described as a continuum with shades of
grey rather than with a binary (dichotomous), black-or-white cut-off.
The prevalence of HRR depends on the chosen cut-off and ranges from 85% (with < 80%)
to 40% (with HRR < 50%). Our results corroborate previous evidences with the strengths
of a large sample size (917 patients), long follow-up (median 89 months) which allowed
us to analyse death as the only significant endpoint, and the addition of SE which al-
lowed to evaluate stress imaging parameters of established prognostic value recognized by
guidelines such as LVOTO and RWMA.
Exercise-induced hypotension was not a predictor of death, in keeping with recent
evidences [24].
4.2. Clinical Implications
Resting transthoracic and SE are especially attractive for the purpose of risk stratifica-
tion in HCM, when serial follow-up examinations are often needed in the same patient [18].
As a consequence, facilities and skills for ESE are usually available in specialist HCM
centres [24]. On top of imaging information during ESE, HRR is a simple, common,
imaging-independent, and easily diagnosed parameter that presently finds no place in
recommendations of scientific societies on the applications of SE in HCM [2,14]. It can
be added to the standard approach including RWMA and LVOTO without any extra-
need of technology or training, since it can be extracted from the 12-lead EKG or even
in the one-lead EKG. HRR information is independent of concomitant therapy (off or on
beta-blockers).
4.3. Pathophysiology of Blunted HRR in HCM
Cardiac autonomic nervous system can be impaired in patients with HCM [25,26].
HCM patients show a reduced beta-receptors density and function, with initial exaggerated
response to sympathetic stimulation which may later progress to receptor desensitiza-
tion [27–30]. A blunted HRR can be therefore considered a marker of reduced sympathetic
reserve often associated with higher baseline levels of sympathetic activity which can
be detrimental in HCM for many reasons. Increased sympathetic activity and increased
cardiac norepinephrine may increase myocardial cell growth, disarray and scarring, induce
myocardial ischemia through alpha-adrenergic coronary constriction and increase the rate
of spontaneous depolarizations in myocardial cells with resulting electrical instability [20].
4.4. Study Limitations
There was no core lab reading but data were entered by each centre at the time of
enrolment, as required by an effectiveness real world study [15].
HRR was not contemplated in the risk stratification strategy of initial protocols, but rest
and peak heart rate are an obligatory part of the minimum data of stress echo methodology
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since the beginning, and this allowed to retrieve the data, although with no information on
heart rate recovery which may provide an index of parasympathetic activity [22].
We only analysed all-cause death which is the strongest and more reliable of all
possible outcome measures [18]. In theory, HRR is especially suited to detect sudden
cardiac death due to cardiac autonomic unbalance [19] but it also predicts non-cardiac
and cancer death [16,17], which are the prevailing causes of death in contemporary HCM
patients [31].
Genetic testing was not systematically performed, and it would not have been feasible
since the recruitment window started in 1984.
Dose and type of beta-blockers, calcium-antagonists and other drugs possibly interfer-
ing with chronotropic response were not available. However, the prognostic value of HRR
was documented in populations both on and off beta-blockers.
5. Conclusions
HRR predicts outcome in HCM in a manner independent from other established
predictors such as age and maximal wall thickness. HRR outperformed LVOTG and
exercise-induced hypotension for predicting survival, and was independent of and ad-
ditive to RWMA. The likely pathophysiological substrate of a blunted HRR is a reduced
sympathetic reserve leading to autonomic system unbalance and life-threatening vulnera-
bility to electrical instability.
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